IRAK4 and acute myeloid leukemia: Moreover, the orally available small-molecule IRAK4 inhibitor, CA-4948 (emavusertib), is currently in phase I trials in NHL, MDS, and acute myeloid leukemia (AML), as it demonstrated anti-cancer efficacy signals and a favorable safety profile in preliminary clinical data (NCT04278768; NCT03328078; NCT05178342).